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The  chemical  specificity of the  colchicine-binding site 
of  tubulin is less stringent  for  the  presence of the B- 
ring  than  the A- and  C-rings of colchicine.  Colchicine 
analogues with modifications in the  B-ring  bind to tu- 
bulin at the same site as colchicine. Analogues with 
smaller  or no substituents  in  the  B-ring bind  tubulin 
remarkably faster than  colchicine.  Thus,  a  compound 
without the B-ring [2-methoxy-5-(2’,3’,4’-trimethoxy- 
phenyl)tropone] binds tubulin even at 4 “C and the 
binding is almost  instantaneous at 37 “C. Colcemid  and 
2-methoxy-5-(2’,3’,4’-trimethoxyphenyl)tropone bind 
reversibly to tubulin,  whereas  colchicine  and  desace- 
tamidocolchicine  bind  almost  irreversibly,  suggesting 
that  the  size of the  B-ring  moiety of colchicine is not 
related to the  reversibility of binding. 
We conclude  that  although  the  presence of the  B-ring 
of  colchicine  does  not  appear to be  an essential prereq- 
uisite for the  drug-tubulin  interaction,  the  B-ring  sub- 
stituents play an important role in determining the 
binding  properties  of  colchicine to tubulin. 
Colchicine binds to native tubulin with a stoichiometry 
approaching 1 mol of alkaloid per mol of tubulin dimer (Mr 
= 110,000). Most of the published work  involving binding of 
colchicine and its structural analogues to tubulin emphasize 
the importance of the role of the trimethoxyphenyl (A-ring) 
and tropolone (C-ring) moieties (1-3). Podophyllotoxin which 
resembles colchicine only in the A-ring inhibits colchicine 
binding to tubulin (1, 2, 4 ) .  Insertion of a buLky group in the 
A-ring of colchicine, as in colchicoside, causes complete loss 
of binding (1, 2). Similarly, the requirement of the tropolone 
ring (C-ring) is highly stringent.  Thus, Iumicolchicine  which 
has an altered C-ring does not bind tubulin (4). Replacement 
of the tropolone by a phenyl ring produces the totally inactive 
drug colchinol (5). Even slight manipulation of the tropolone 
structure, by interchanging the positions of the carbonyl and 
methoxy groups, produces an inactive analogue, i.e. isocolchi- 
cine, having no tubulin-binding activity (1). On the other 
hand, colchicine analogues modified at, or depleted of, the B- 
ring are known to have potent antimitotic activity which 
apparently rules out any major role of the B-ring in the 
antimitotic activity of colchicine (3). Nevertheless, a minor 
change in the B-ring substituents may significantly change 
the binding mechanism and nature of the drug-tubulin com- 
plex formed as has been reported from this laboratory (6). 
Thus, colcemid binds tubulin fairly rapidly and reversibly, 
whereas colchicine  binds  slowly, requiring long incubation at 
37 “C  to attain equilibrium (7-10) and the binding  is reversible 
with difficulty (4, 11). This finding prompted us to investigate 
whether the B-ring and  its  substituents have any role  on the 
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rate and reversibility of the reaction. 
It was found on the basis of the present study, using 
colchicine analogues differing in the B-ring only, that the 
smaller the substituents  are on the B-ring, the  faster is the 
rate of binding of the analogue to tubulin. Moreover, unlike 
colchicine, the analogues with modified B-rings bind tubulin 
even at 4 “C. 
MATERIALS  AND  METHODS 
Tubulin was purified from goat brain in PMG buffer (10 mM 
potassium phosphate, pH 7.0, 10 mM MgCl2, 0.1 mM GTP) by the 
procedure of Weisenberg et al. (12), except that DEAE-cellulose was 
used instead of DEAE-Sephadex. The active fractions, as judged from 
a colchicine binding assay, were pooled, concentrated by overnight 
dialysis a t  0 “C against 8 M glycerol in either binding buffer (PMG) or 
polymerization buffer (100 mM Mes‘ pH 6.4, 1.0 mM EGTA, 1.0 mM 
GTP, and 0.5 mM  MgC12) depending on the nature of subsequent 
experiments, and  stored at -20 OC. The purity of tubulin was checked 
by polyacrylamide gel electrophoresis in  0.1% sodium dodecyl sulfate 
according to Weber and Osborn (13). 
Protein  concentrations were determined as described by Lowry et 
al. (14), using bovine serum albumin as a  standard. The  GF/C filter 
paper disc assay method described by Banerjee and Bhattacharyya 
(6) for colcemid and colchicine binding was used with a minor modi- 
fication for monitoring the effect of the unlabeled analogues (which 
interact with tubulin  either reversibly or irreversibly) on IgHIcolchi- 
cine-binding to tubulin.  Whatman GF/C filter paper discs were ini- 
tially washed with 1 ml of cold (2-4 “C) PM buffer (10 mM potassium 
phosphate, pH 7.0, and 10 mM MgCld, taking care not to dry the 
papers. Then, 1 ml of PM buffer containing M colchicine was 
poured on the fdter  paper to which 100 pl of the sample was added 
and allowed to drain off under mild suction. The filters were then 
rinsed 3 times with 3 ml of cold PM buffer by mild suction, dried, and 
counted in 5 ml of toluene-based fluor. Identical blanks, without 
tubulin, were prepared  and necessary corrections were made. 
Fluorescence was measured as described by Bhattacharyya and 
WoM (1) in  a  thermostated chamber at 37 “C in a Perkin-Elmer MPF 
44B spectrofluorometer with an excitation wavelength of 353 nm. 
Microtubule assembly was measured spectrophotometrically in pol- 
ymerization buffer containing 4 M glycerol at 37 “C in a  Cary 17D 
spectrophotometer recording at 400 nm. The polymerization was 
initiated by raising the temperature of the reaction mixture from 0- 
37 “C directly in the thermostated chamber of the spectrophotometer. 
Tritiated colchicine (ring  C, [’Hlmethoxy), having a specific 
activity of 5 Ci/mmol, was the product of  New England Nuclear Corp. 
Colcemid was a gift from Dr. J. Wolff of the National Institutes of 
Health. The  other colchicine analogues, desacetamidocolchicine and 
2-methoxy-5-(2’,3’,4’-trimethoxyphenyl)tropone w re kindly supplied 
by Dr. T. J. Fitzgerald of Florida A and M University. Unlabeled 
colchicine and  GTP (grade 11s) were products of Sigma Chemical CO. 
GF/C filter papers were obtained from Whatman Ltd., England. 
RESULTS AND DISCUSSION 
B-ring Specificity of Colchicine Binding Site 
To elucidate the role of the B-ring of colchicine in its 
binding to tubulin,  structural analogues were chosen which 
’ The abbreviations used are: Mes, Z-(N-morpholino)ethane- 
sulfonic acid; EGTA, ethylene glycol bis(P-aminoethyl ether)- 
N,N,N,N-tetraacetic acid. 
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differ from colchicine in the B-ring only (Fig. 1). Among these 
compounds, colchicine and colcemid have been widely used in 
the  study of the tubulin-microtubule  system. Analogues 
such as desacetamidocolchicine and 2-methoxy-5-(2’,3’,4‘-tri- 
methoxypheny1)tropone are reported (3) to inhibit tubulin 
polymerization, but  their effects on the colchicine binding site 
of tubulin  have  not  been tested.  The ability of all these dnigs 
to inhibit microtubule assembly both in uitro and in vivo 
apparently rules out  any major role of the B-ring of colchicine 
in its antimicrotubular  activity (3). Nevertheless, these find- 
ings do  not  furnish any information as to  whether and how 
the B-ring of colchicine affects the mechanism of colchicine- 
tubulin  interaction. Thus,  it was important  to examine first 
whether all the chosen compounds bind to tubulin at  the  same 
site  as colchicine. The B-ring specificity of colchicine-tubulin 
interaction was studied by measuring the prevention of 
[3H]colchicine binding by the analogues with modified B-ring 
(Fig. 1) and  the  data were analyzed by  modified Dixon plots 
(Fig. 2). From the results, it is evident that [‘H]colchicine 
binding is inhibited competitively by colcemid, desacetami- 
docolchicine, and 2-methoxy-5-(2‘,3’,4’-trimethoxyphenyl)- 
tropone yielding apparent K, values of 1.4 X M, 0.32 X 
Thus,  it  appears from this study  that, unlike the A-ring and 
the C-ring, a wide variation in the B-ring moiety is tolerated 
by the colchicine binding site of tubulin.  Even 2-methoxy-5- 
(2’,3’,4’-trimethoxyphenyl)tropone, which is devoid of the  B- 
ring of colchicine, showed a considerable inhibition of colchi- 
cine binding. This suggests that the site of interaction of 
colchicine on  tubulin is embodied in the bicyclic derivative, 2- 
methoxy-5-(2’,3’,4’-trimethoxyhenyl)tropone. 
M, and 1.6 X M, respectively. 
Role of the B-ring Moiety on the Rate of Colchicine. 
Tubulin  Interaction 
Colchicine binding to tubulin is a slow process which needs 
long incubation at 37 “C for equilibration (7-11). There is no 
direct evidence to explain this unusual  property,  although it 
has been interpreted  as showing the requirement for a favor- 
able conformation of tubulin molecule for binding (15) or a 
colchicine-induced change  in its conformation (16). However, 
it  has not been settled unequivocally whether the slow binding 
is a  property of the binding site of tubulin which needs long 
incubation at  37 “C for conformational change to occur or is 
due  to  the unfavorable conformation of the colchicine mole- 
cule. We therefore examined these possibilities using the  B- 
ring-modified colchicine analogues. 
It is already known that although neither colchicine nor 
tubulin  exhibit  any fluorescence in  PMG buffer (pH 7.0) when 
excited at  the absorption  peak of colchicine, there is striking 
induction of fluorescence when these two compounds are 
incubated  together at  37 “C (1). So it was thought appropriate 
to examine the fluorescence property of the colchicine ana- 
logues which interact with tubulin. It was found, using a 
solution containing tubulin and 5 p~ drug in  PMG buffer (pH 
7.0), that colcemid, desacetamidocolchicine, and 2-methoxy-5- 
O W 3  o w 3  
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FIG. 1. Structure of colchicine and some of its analogues. 
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FIG. 2. Modified  Dixon plot demonstrating the effect of col- 
chicine analogues on the colchicine binding to tubulin. The 
concentrations of the analogues present is plotted against the recip- 
rocal of the bound [3H]colchicine at several concentrations of 
[3H]colchicine: (M) 1 PM; (A-A) 2 PM; (W) 4 p ~ .  The 
reaction mixtures containing tubulin (0.21 mg/ml) and the drugs as 
indicated were incubated at 37 “C for 90 min. 
(2’,3’,4’-trimethoxypheny1)tropone fluoresce on combination 
with tubulin, with the emission maxima in the same region as 
in the case of colchicine. However, fluorescence of the col- 
cemid-tubulin complex had a comparatively low quantum 
yield.2 Furthermore, like colchicine, the  other compounds did 
not fluoresce in the absence of tubulin. So, it was convenient 
to measure the time of equilibration of binding of these ligands 
to tubulin by this method.  Tubulin was  mixed with 5 p~ drug 
at 37 “C in  a  temperature-controlled  spectrofluorometer, and 
the emission spectra were measured at  different time  intervals. 
It is evident from Fig. 3 that, while the binding of colchicine 
was not complete even within 75 min, colcemid binding to 
tubulin was complete in about 20 min. A similar result was 
also obtained for colcemid by monitoring binding of the ‘H- 
labeled drug to tubulin.’ In  the case of desacetamidocolchi- 
cine, maximum fluorescence, indicating maximum binding, 
was obtained in about 15 min. Interestingly, binding of 2- 
methoxy-5-(2’,3‘,4’-trimethoxyphenyl)tropone (a compound 
which is devoid of the B-ring) to tubulin was very rapid since 
within 1.5 min maximum fluorescence was obtained which did 
not  increase further with time. 
From the fluorescence data  it is evident that depletion of 
substituents from the B-ring of colchicine molecule causes 
concomitant  enhancement in the  rate of its binding to tubulin 
and reduction in the time of equilibration. Thus,  the question 
arises as  to whether the slow binding of colchicine is due  to  its 
extreme structural rigidity, since  a compound (2-methoxy-5- 
(2’,3’,4’-trimethoxyhenyl)tropone), which can assume an in- 
finity of conformations due  to free rotation  around the single 
bond, binds tubulin almost instantaneously. However, this 
seems unlikely, because the rigidity imparted  to colchicine 
molecule by the B-ring, which anchors the A- and C-rings 
K. Ray, B. Bhattacharyya,  and B. B.  Biswas, unpublished obser- 
vation. 
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FIG. 3. Time dependence of fluorescence emission spectrum of the drug-tubulin complex. The reaction mixture contained 9.4 FM 
tubulin  and 5 PM drug in PMG buffer (pH 7.0). The numbers accompanying each curue refer to  time (in minutes) of incubation of the reaction 
mixture at 37 "C.  The excitation wavelength was 353 nm. 
TABLE I
The effect of temperature  on  binding of colchicine analogues to 
tubulin 
The reaction mixtures containing 10 p~ tubulin and 5 pM drug were 
incubated in PMG buffer (pH 7.0) at 37 "C or 4 "C for 60 min. 
Fluorescence intensity was measured at  430 nm and proper correc- 
tions were made for blank (minus  tubulin). The excitation wavelength 
was 353 nm. 
Colchicine analogues 
Per cent of max- 
cence 
Colchicine 37 "C 100 
4 "C 9 
Colcemid 37 "C 100 
4 "C Inconclusive 
Desacetamidocolchicine 37 "C 100 
4 "C 73 
2-Methoxy-5-(2',3',4'-trimethoxy- 37 "C 100 
pheny1)tropone 4 "C 100 
Condition imai fluores- 
together, is present also in colcemid and desacetamidocolchi- 
cine. Rather,  it is possible that gradual depletion of substitu- 
ents from the B-ring results in the formation of analogues of 
favorable conformation for binding. In fact, the configuration 
of the B-ring, when present, is important  as evidenced by the 
remarkable potency difference between the  (+)-(unnatural) 
and  (-)-enantiomers of colchicine for both tubulin (17) and 
the anti-colchicine antibody (18). 
Next, we tested  whether any of these colchicine analogues 
bind to  tubulin at 4 "C where no conformational change of 
tubulin was expected to occur. So, 5 ~ L M  drug was mixed with 
10 ,UM tubulin and exposed for 60 min either at 37 "C or at 
4 "C. The fluorescence due  to the drug-tubulin complex  was 
measured. It is evident from Table I that in the case of 
colchicine, there was very little fluorescence in the sample 
0 15 30 45 60 75 90 
TIME (minute) 
FIG. 4. Reversibility of binding of colchicine analogues to 
tubulin. Tubulin (3.6 PM) in PMG buffer (pH 7.0) was preincubated 
at 37 "C for 45 min in the absence (&--A) or presence of colchicine 
thoxypheny1)tropone (M), desacetamidocolchicine O " O ) ,  
analogues (12.5 p ~ ) :  colcemid (A-A), 2-methoxy-5-(2',3',4'-trime- 
colchicine (M). The assay mixture containing only tubulin  (con- 
trol tube) or drug-tubulin complex  was further incubated with 
[3H]colchicine (1 PM) at 37 "C for different times as indicated in the 
figure. Tubulin bound radioactivity was determined by GF/C filter 
paper disc assay as described under "Materials and Methods." 
incubated at 4 "C, whereas desacetamidocolchicine binding at 
4 "C was about 73% of that  at 37 "C. Interestingly, 2-methoxy- 
5-(2',3',4'-trimethoxyphenyl)tropone binding to tubulin was 
complete at 4 "C and had exactly the same value as at 37 "C. 
However, nothing conclusive  was found in the case of colcemid 
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FIG. 5. Reversibility of inhibition of tubulin polymerization 
by colchicine analogues. Tubulin (2.6 mg/ml) in 4 M glycerol  was 
allowed to polymerize at 37 "C in a buffer containing 100 mM Mes 
(pH 6.41, 1 mM EGTA, 0.5 mM  MgC12 and 1 mM GTP: A ,  in the 
absence of drugs (H) or in the presence of 10 p~ drug (colchicine 
(c"O), colcemid (M), desacetamidocolchicine (A-A), 2- 
methoxy-5-(2',3',4"trimethoxyphenyl)tropone (A-A)). After mon- 
itoring polymerization at 400 nm  by incubating the reaction mixture 
at 37 "C for 45 min, the microtubules formed were depolymerized by 
exposing the  tubes containing the reaction mixture at 0 "C for 10 min. 
Then 20 mg of charcoal (previously washed with 100 mM Mes (pH 
6.4), 1 mM EGTA, and 0.2% bovine serum  albumin) was added per 
tube, kept for 30 min at 0 "C with occasional stirring, and then spun 
to pellet the charcoal. B, the charcoal-free reaction mixtures were 
again incubated at 37 "C to monitor polymerization of tubulin. 
because of the weak fluorescence of the tubulin-colcemid 
complex. These observations seem to exclude the possibility 
of  slow conformational change of tubulin as an essential 
prerequisite for its binding to  the analogues like desacetami- 
docolchicine and 2-methoxy-5-(2',3',4'-trimethoxyphenyl)tro- 
pone. So, it seems probable that  the slow binding of colchicine 
to tubulin, which is reported to occur with accompanying 
change in tubulin conformation (16), might be due to an 
unfavorable conformation of the colchicine molecule. Re- 
cently, Detrich  et al. (19) have shown that  the circular dichroic 
spectrum of colchicine changes on binding to tubulin, indicat- 
ing that a conformational change of colchicine occurs on 
binding. Wolff et al. (18) have observed that, in contrast  to 
the slow  binding of colchicine to tubulin even at 37 "C, the 
drug binds to  its antibody readily at 4 "C. 
Reversibility 
Unlike colchicine binding, colcemid binding to tubulin is 
reversible (6). This finding suggests that, in addition to its 
effect  on the  rate of colchicine-tubulin interaction, the B-ring 
of colchicine might play a significant part in the  nature of the 
drug-tubulin complex formation. To explore this possibility, 
the colchicine analogues were tested for their reversibility of 
interaction with tubulin. 
By Binding Experiments-The extent of reversibility of 
interaction of the analogues with tubulin were quantitated by 
chasing the preformed analogue-tubulin complex with ['HI- 
colchicine. For this, tubulin was preincubated for a fixed time 
with the analogues (12.5 PM) to be tested and then chased 
with [3H]colchicine (1 pM) for different time intervals by 
further incubation at 37 "C. The rate of formation of the 
[3H]colchicine-tubulin complex was taken as a measure of 
reversibility of interaction between the analogue and tubulin. 
As shown in Fig. 4, it  appears that  the interaction of tubulin 
with colcemid is maximally reversible, followed by the com- 
pound with the open B-ring, i.e. 2-methoxy-5-(2',3',4'-trime- 
thoxypheny1)tropone. Desacetamidocolchicine is as irreversi- 
ble as colchicine. 
By Polymerization-Tubulin was allowed to polymerize 
both in the presence and absence of the drugs. It was thus 
found that 10 PM colchicine and colcemid inhibited polymer- 
ization partially in  buffer containing 4 M glycerol  while desa- 
cetamidocolchicine and 2-methoxy-5- (2',3',4'-trimethoxy- 
pheny1)tropone inhibited polymerization of tubulin com- 
pletely (Fig. 5). Such an observation can be  explained by the 
faster rate of binding of the  latter two drugs. On removal of 
the free drugs from the assay mixture by bovine serum albu- 
min coated charcoal, after depolymerization (at 0 "C) of mi- 
crotubule formed, it was found that tubulin treated with 
colcemid and 2-methoxy-5-(2',3',4"trimethoxyphenyl)tropone 
only  could again polymerize, indicating reversibility of inter- 
action. These results agree with the K; values of the drugs 
(Fig. 2). However, on the basis of the results presented here, 
it is apparent  that  the size of the B-ring moiety of colchicine 
cannot be related to the reversibility of interaction. 
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